Endra Life Sciences Inc (NDRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -8,601 | -5,500 | -2,943 | -13,179 | -9,890 |
| Depreciation Amortization | 214 | 144 | 71 | 234 | 167 |
| Other Working Capital | 266 | 88 | 128 | -1,026 | -867 |
| Other Operating Activity | 746 | 493 | 237 | 1,201 | 909 |
| Operating Cash Flow | $-7,374 | $-4,775 | $-2,507 | $-12,769 | $-9,681 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -27 | -27 | -27 | -203 | -164 |
| Investing Cash Flow | $-27 | $-27 | $-27 | $-203 | $-164 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 5,847 | 4,733 | N/A | 8,400 | 8,400 |
| Financing Cash Flow | $5,847 | $4,733 | $N/A | $8,400 | $8,400 |
| Beginning Cash Position | 4,889 | 4,889 | 4,889 | 9,462 | 9,462 |
| End Cash Position | 3,335 | 4,820 | 2,355 | 4,889 | 8,016 |
| Net Cash Flow | $-1,555 | $-70 | $-2,534 | $-4,572 | $-1,445 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,374 | -4,775 | -2,507 | -12,769 | -9,681 |
| Capital Expenditure | -27 | -27 | -27 | -203 | -164 |
| Free Cash Flow | -7,401 | -4,802 | -2,534 | -12,972 | -9,845 |